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Weight gain associated with hormonal contraception use m adolescents 1s not 
different from control 
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Abstract: The use of hormonal contraception is commonly associated with weight gain. The purpose of this retrospective study was 
to explore the association between the use of hormonal contraception and weight change in an outpatient adolescent patient 
population in Lexington, Kentucky. Data were gathered from the charts of 259 adolescent female patients seen in an outpatient 
adolescent clinic for up to 72 months. At the initial visit, all patients were evaluated for risk-taking behavior and received preventive 
counseling. Patients were categorized as either contraception users or non-users (control group). Contraception users were subdivided 
into Depot Medroxyprogcstcronc Acetate (DMPA) user group or non-DMPA contraception user group. The latter group included 
patients using oral contraceptive pills, transdermal contraceptive patch, intravaginal. contraceptive ring, or other forms of hormonal 
contraception. Following the initial vis it, all contraception users (DMPA and non-DMPA) visited the clinic every three- or six-
months for follow-up. During the follow-up visits, patient weight was recorded and the patient received counseling services by a 
physician, a licensed psychologist, and/or a nutritionist as deemed appropriate. Data were entered in Microsoft Excel and analyzed 
using Statistical Analysis Software. The results showed no significant difference in weight gain between groups. We hypothesize that 
hormonal contraception in adolescent patients, coupled with clinical intervention in form of counseling and regular monitoring, over 
an extended period (longer than 24 months) is not associated with significant weight gain. 
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INTRODUCTION 
In its most recent release, the American Academy of 
Pediatrics Policy on Contraception and Adolescents 
continues to recommend prOVISion of hormonal 
contraception to adolescents by their primary care 
physicians (1 ,2). Hormonal contraception is available in 
various forms including combined oral contraceptive 
pills, injections, skin patches, subcutaneous implants, 
and vaginal rings (3). Oral contraceptive pills (OCPs) 
are the most popular method among adolescents and 
their protective, therapeutic, and non-contraceptive uses 
in gynecologic diseases are well documented (2,4-6). 
Depot Medroxyprogesterone Acetate (DMP A) is the 
major injectable contraceptive in the United States ( 4). 
DMPA injections, similar to OCPs, offer safe, effective, 
convenient, and reversible birth control choices (7). 
DMPA injection use is also favorable to use in 
adolescents who have low compliance rates with OCPs 
(8) and are gaining appeal among adolescents, because 
of their effectiveness (9). 
Despite the proven benefits of hormonal contra-
ceptives, a number of controversies have emerged due 
to their side effects. The OCPs are commonly associated 
with cardiovascular complications, breakthrough 
bleeding, and migraine headaches (2-4, 1 0). Injectable 
contraceptives, on the other hand, are commonly 
associated with vaginal bleeding ( 11, J 2), decreased 
bone mineral density, and abdominal pain (1 3). Both 
oral and injectable contraceptives have been associated 
with weight gain (3-5, 10,1 I, 13-16). 
Numerous retrospective and prospective clinical 
studies conducted in the United States explored the 
relation between hormonal contraception and weight 
gain. A 24 month study by Berenson et at ( II) of 16-33 
year old females found that the odds of weight gain for 
patients using OCPs or DMPA after 24 months were 
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1.19 and 2.27, respectively, compared with the control 
group odds of l.OO. In another 12 month study, 
adolescent Norplant implant users gained more weight 
than oral contraceptive users (8.7 vs. 4.2 pounds 
respectively) (17). As for DMPA usc, a 30-month 
prospective experimental study of low socioeconomic 
status adolescent African American patients, weight 
gain was the most commonly perceived side effect and 
the primary reason for discontinuation of treatment (18). 
The finding of weight gain seems to be universal; 
Austrian high school adolescents who started using the 
pill at a mean age of 16.0 ± 0.9 years noted weight gain 
as a s ide effect in addition to an increase in breast size, 
fatigue, and depression ( 19). 
Contrary to the findings above, other studies showed 
no significant change in weight with the use of 
hormonal contraception. A randomized, parallel-group, 
multicenter study showed that use of OCPs does not 
substantially affect body weight for most women after 
13 cycles of use (20). A study of adolescent and young 
women using oral contraceptive pills or intra-uterine 
devices (fUD) as a control group, showed no significant 
difference between the OCP and IUD groups in initial 
weight and weight after one year of use (21 ). A more 
recent study comparing OCP use to a placebo-controlled 
group in adolescent subjects showed that changes in 
body weight and the incidence of estrogen-related side 
effects in the OCP group after six cycles were not 
significantly different from placebo-controlled group 
(22). Due to the numerous controversies in the literature 
regarding weight gain due to the use of contraceptives, 
we aim to determine once and for all the effects of 
contraceptives on weight gain. To this end, we used the 
patient charts of patients who were on different oral 
contraceptive use for at least one year, as well as a 
'contro!' group who are not using contraceptives. 
METHODS 
Data were gathered from the charts of 313 adolescent 
female patients seen in an outpatient adolescent clinic in 
Lexington, Kentucky. At the initial visit, all patients were 
evaluated for risk-taking behavior using the Perkins' 
Adolescent Risk Screen (P AR.S) form (I). P AR.S is a 
validated screen that assesses a variety of health-related 
variables, such as Body Mass Index (BMl), nutrition, 
drug use, and sexual activity, in addition to other 
biopsychosocial factors (23). Following this assessment, 
all patients received preventive counseling by a certified 
psychologist in the clinic. 
Hormonal contraception including Depot Medroxy-
progesterone Acetate (DMPA) method or non-DMPA 
methods (including oral contraceptive pill, patch, ring or 
other forms) was prescribed to a subset of these patients 
following consultation with the attending physician and 
the patient. Follow-up visits were scheduled every three 
months for DMPA contraception users and every 3-6 
months for non-DMPA contraception users. During 
follow-up visits, patient weight was recorded and other 
screening tests such as HPV (human papillomavirus) 
screening were conducted. In addition, every patient 
received counseling by a team composed of a 
psychologist, social worker, nutritionist, and a nurse 
practitioner. Data collected from patient charts included 
demographic information, weight data, HPV screen 
results, risk taking behavior, and pertinent medical 
conditions. 
Data were entered and BMT was calculated in 
Microsoft Excel. Data were entered as "missing value" 
for patients who discontinued hormonal contraception 
or discontinued visiting the clinic. Statistical Analysis 
Software (1) was used to analyze the data coded in 
Excel. The demographic data were analyzed using 
descriptive statistical measures. A one-way ANOV A 
statistical test was performed to compare weight change 
and BMI change in the hormonal contraception user 
group vs. the control group at the initial v isit and every 
year thereafter. The same analysis was conducted to 
compare the DMPA vs. non-DMPA groups. The two 
groups were compared at the end of years I , 2, 3, 4, 5, 
and 6 using ANOVA Scheffe's method P < .05 was 
considered statistically significant. 
Exclusion criteria: patients who used contraception 
for less than one year or switched contraception 
methods in less than one year were also excluded. Using 
these criteria, the final number of patients in the study 
was 259. 
RESULTS 
The age range of the patients included in the study was 
12-21 years at the beginning of the study. The mean age 
was 18.1 ± 2.4 years. The median value for age was 
16.5 years and the mode value was 19.5 years. Of the 
patients, 98% reported their status as s ingle, 2% as 
married or engaged. In terms of racial distribution, 49% 
of the patients were Caucasian, 50% African American, 
and I% Hispanic. Insurance type was used as an index 
of socioeconomic status. The vast majodty of patients 
(72%) were Medicaid recipients, whereas 21% were 
private insurance carriers. The remaining 7% of patients 
had no insurance plan and were recipients of fmancial 
assistance. With respect to smoking status, most patients 
(66%) were non-smokers whereas 34% were smokers. 
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Table I: Demographic characteristics of subjects at the 
beginning of the study (n=313) 
Age 
Mean±S.D. Median Mode 
15.8±2.2 16.0 16.0 
Minimum Maximum 
Age Range 
8.5 21.0 
Single Married 
Marital Status 
97.2% 1.8% 
Caucasian 
African 
Other 
Race American 
47.9% 47.2% 4.9% 
Private None Medicaid 
Insurance Status 
22.4% 6.3% 71.3% 
Yes No 
Smoking Status* 
30.6% 69.4% 
Yes No 
Substan..:e Abuse ... 
25.1% 74.9% 
Contraception group User Non-User 
Subjects pe group (n) 215 98 
*Other includes Hispanic, Native American, Oriental, and biracial 
patients. 
**The smoking status data not available for 15% of the patients. 
••• Substance abuse data not available for 30% of the patients. 
However, the smoking slatus was missing for 15% of all 
subjects in the study. Regarding substance abuse, 26% 
of patients admitted abusing alcohol, drugs, or both , 
whereas 74% of patients denied abusing either alcohol 
or drugs (see table 1). 
As previously mentioned, patient weight (in pounds) 
was recorded at the initial and each follow-up visit. 
Weight changes per patient were calculated at the end of 
each year for patients in the contraception user and non-
user (control) groups. A significanl difference in the 
weight changes between the two groups was seen at the 
end of year I (p = .03). In contrast, no significant 
differences were observed in the following years (see 
graph 1). 
Subsequently, the BMl calculation was used to 
compar:: patients in the contraception user and control 
groups as described above. No significant difference 
was found between the two groups at any time point, 
including year I (see graph 2). The height variable was 
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Graph 1: Weight change in 
pounds per year in contraception 
user and control groups. 
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Graph 2: Body Mass lndex (BMl) Year 
change per year in both contra- 1 
cepbon user and control groups. 2 
3 
4 
5 
6 
N per group 
Users Controls 
214 42 
136 22 
76 10 
38 4 
16 3 
9 2 
5 6 
N per group 
Users Controls 
96 34 
53 12 
33 6 
15 3 
6 3 
2 2 
not documented for all patients, therefore accounting for 
decrease in then value of patients in this graph. 
DISCUSSION 
As mentioned previously, the literalure is abundant with 
conflicting results on the association of hormonal 
contraception with weight change in adolescents (I I, 13-
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19,22). The disparity between these results could be due 
to a number of factors. First, the duration of most 
studies reported to date is relatively short. Most studies 
did di not extend past 24 months (II), 13 cycles of use 
(20), one year of use (17,21,24) or six cycles of use 
(22). Only one study tracked patients for a duration of 
30 mor!hs. This study, however, had a significant drop-
out rate of subjects toward the end of the study (18). 
Monitoring weight changes for a longer duration in 
adolescents is important because of the developmental 
changes that accompany the onset of puberty. The 
growth spurt during adolescence is associated with 
weight and height velocities greater than between the 
ages of 5 and I 0 years (25). This suggests that 
susceptibility to hormonal contraception may be 
selectively accentuated in early adolescence, which is 
associated with the onset of menarche and the use of 
hormonal contraception. Rather than causing a net 
weight gain, hormonal contraception could accelerate 
pubertal development, leading to the final body weight 
set point that the same subject would have attained 
eventually if not placed on hormonal contraception. 
However, the short duration of studies in this field 
precludes such a viable conclusion. 
The provision of counseling may be an effective 
intervention preventing weight gain. The present study 
is quite unique because unlike other studies, the subjects 
were provided with preventive counseling at the initial 
visit and continuous counseling at each follow-up visit. 
The counseling each subject received addressed a wide 
variety of issues such as nutrition, dealing with the side 
effects of contraception, ensuring compliance, and 
addressing psychological issues related to the well-
being cf the patient. In contrast, continuous counseling 
was not reported in other studies investigating the 
association between hormonal contraception and weight 
gain (3-5, I 0,11, 13-16). Davies et al (26) recommended 
that clinicians promote delayed sexual activity and 
provide counseling to adolescents considering hormonal 
contraception. The American Association of Pediatrics 
also continues to recommend preventive, but not 
continuous counseling to this adolescent population 
regarding the use of contraceptives (2). 
The initial weight before using hormonal contra-
ception may be associated with the degree of weight 
gain in adolescents. For example, overweight in child-
hood or excessive body mass increment during 
pregnancy are risk factors of obesity in the later period 
of life (27). By analogy, one could hypothesize that 
overweight adolescents are more susceptible to weight 
gain induced by hormonal contraception. Risser et aJ 
(24) found that adolescent subjects who gained> 5% of 
their baseline weight at 3 months were at high risk 
(93%) of gaining even more weight by one year. 
In conclusion, earlier studies on the association of 
hormonal contraception and weight changes in 
adolescents reported significant weight gain due to 
contraceptives. Despite their validity, the duration of 
such studies, 6-24 months, remains relatively short in 
the context of adolescent development and thus the 
study is limited in its interpretive ability. Furthermore, 
although most srudies provided preventive counseling at 
the initiation of hormonal contraception, none of offered 
a continuation in psychological counseling services. Our 
retrospective study is the first to address this question 
beyond 24 months and to show that weight gain in 
hormonal contraception users is not significantly 
different from the control group for up to 72 months. In 
addition, our study is unique in offering psychological 
counseling to patients dming follow-up visits, which 
suggests that psychological counseling may be an 
effective clinical intervention preventing the weight gain 
traditionally associated with hormonal contraception. 
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